ArticleTherapeutics and clinical risk management2025
Recurrent Rhegmatogenous Retinal Detachment: Characteristics, Risk Factors, and Outcomes.
Article in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recurrent rhegmatogenous retinal detachment: incidence, established and emerging risk factors, and clinical outcomes.BMC ophthalmology · 2026Article
- Does axial length drive retinal displacement after repair of rhegmatogenous retinal detachment following phacoemulsification.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Rhegmatogenous retinal detachment (RRD) is a severe retinal disorder that can lead to vision impairment and potentially blindness. After RRD repair surgery, every vitreoretinal surgeon aims to understand the characteristics of the RRD and to achieve permanent flattening without any recurrence. This study aimed to identify factors predisposing patients to recurrent RRD. Patients and Methods: This retrospective study was conducted at King Abdullah University Hospital and included all patients who underwent pars plana vitrectomy for RRD repair between January 2015 and December 2023. All demographic, clinical, operative, and outcome data were extracted. The primary outcome was to assess the risk factors affecting the recurrence of RRD. The secondary outcome included factors affecting the final status (flat or detached) of the retina. Using proper statistical methods, the results were generated. Results: The study comprised 348 patients with primary RRD, of whom 44.5% had a previous ocular surgical history. The rate of recurrent RRD was 28.2%. At the last follow-up, 12.6% of the whole patients had persistent retinal detachment without anatomical successful reattachment. Superior-based RRD was the most common type, affecting 145 of 290 patients, and macular involvement in the RRD was observed in 80% of the cases. Recurrent RRD was higher in younger ages, longer duration of symptoms, extensive total type of RRD, involvement of inferior quadrants, detached macula, presence of proliferative vitreoretinopathy, and insufficient prophylactic laser retinopexy (p < 0.05). On multivariate logistic analysis, extensive total RRD, presentation duration, and insufficient prophylactic laser retinopexy were considered as a significant independent factor. Conclusion: Duration of symptoms, involvement of more quadrants, and insufficient laser retinopexy could influence RRD recurrence. These results may coincide with previous literature but provide insights into the newly investigated population. Increasing the awareness of RRD symptoms, identifying high-risk patients, and ensuring prompt surgical intervention may reduce RRD-related complications and decrease the rate of recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.